Oramed Pharmaceuticals Inc
NASDAQ:ORMP

Watchlist Manager
Oramed Pharmaceuticals Inc Logo
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
Watchlist
Price: 3.07 USD 1.15% Market Closed
Market Cap: 122.2m USD
Section:
 

Relative Value

The Relative Value of one ORMP stock under the Base Case scenario is hidden USD. Compared to the current market price of 3.07 USD, Oramed Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORMP Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

62.7
P/S
P/S
Price to Sales
62.7
vs History
47
vs Industry
3
Median 3Y
46.4
Median 5Y
61.3
Industry
2.6
Forward
61.5
More Details
2.9
P/E
P/E
Price to Earnings
2.9
vs History
19
vs Industry
22
Median 3Y
-3.1
Median 5Y
-5.2
Industry
21.6
Forward
2.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-10.4
Industry
16.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
34
Median 3Y
-5.3
Median 5Y
-7.2
Industry
22.5
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
66
vs Industry
71
Median 3Y
0.6
Median 5Y
0.8
Industry
2.3
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
84
Median 3Y
-17.5
Median 5Y
-2.3
Industry
2.9
Forward
-4.6
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
More Details
0.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.7
vs History
41
vs Industry
48
Median 3Y
1.7
Median 5Y
0.2
Industry
13
More Details
0.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.7
vs History
41
vs Industry
47
Median 3Y
1.7
Median 5Y
0.2
Industry
16.6
Forward
0.7
More Details
0.9
EV/OCF
EV/OCF
Enterprise Value to OCF
0.9
vs History
38
vs Industry
46
Median 3Y
2.5
Median 5Y
0.3
Industry
15.8
More Details
0.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.9
vs History
38
vs Industry
36
Median 3Y
2.4
Median 5Y
0.3
Industry
19.1
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
86
Median 3Y
-1.7
Median 5Y
-0.1
Industry
1.9
More Details

Multiples Across Competitors

ORMP Competitors Multiples
Oramed Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
125.4m USD 62.7 2.9 0.7 0.7
US
Eli Lilly and Co
NYSE:LLY
971.9B USD 16.4 52.8 35.5 38
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
509.1B USD 5.5 20.3 16.6 21.5
CH
Roche Holding AG
SIX:ROG
252.3B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP 4.8 29.7 108.2 158.3
CH
Novartis AG
SIX:NOVN
202.4B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
249.5B USD 3.9 13.1 9.3 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.2
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
147B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
US
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
Average P/E: 21.3
2.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.8
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
Average EV/EBITDA: 398.9
0.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
Average EV/EBIT: 1 710.2
0.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3

See Also

Summary
ORMP intrinsic value, competitors valuation, and company profile.
DCF Valuation
ORMP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ORMP stock valuation using valuation multiples.
Wall Street Estimates
ORMP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ORMP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.